[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553572":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":42,"responsibleParty":57,"collaborators":25,"id":59,"slug":25,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":81,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University Hospital Tuebingen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"GLP-1","EXPERIMENTAL","Acute administration of 0.25 mg semaglutide (0.19 ml)",[13],"Other: Subcutaneous GLP1-RA",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Acute administration of 0.19 ml NaCl",[19],"Other: Subcutaneous placebo",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Subcutaneous GLP1-RA","Subcutaneous administration of semaglutide",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Subcutaneous placebo","Subcutaneous administration of NaCl",[15],[31],{"name":32,"affiliation":33,"role":34},"Andreas L. Birkenfeld, MD","Institute for Diabetes research and Metabolic Diseases at the University of Tubingen","STUDY_DIRECTOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Stephanie Kullmann, PhD","CONTACT","0049707129","87703","stephanie.kullmann@med.uni-tuebingen.de",[43],{"facility":44,"status":45,"city":46,"state":25,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"University Clinic Tubingen, Department of Internal Medicine IV","RECRUITING","Tübingen","72076","Germany",{"type":50,"coordinates":51},"Point",[52,53],9.05222,48.52266,{"lat":53,"lon":52},[56],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},{"type":58,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100553572",false,"NCT06487832","Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness","Impact of the Incretin System on Brain Insulin Sensitivity in Humans with Normal Weight, Overweight and Obesity","Inclusion Criteria:\n\n* BMI between 18.5 and 24.9 kg\u002Fm2; and between 27.5 kg\u002Fm2 and 40 kg\u002Fm2\n* Written consent to participate in the study\n* Written consent to be informed about incidental findings\n\nExclusion Criteria:\n\n* Type 1 or type 2 diabetes, LADA, MODY, or cardiovascular diseases such as chronic heart failure, myocardial infarction, status post stroke\n* BMI \\\u003C 18.5 or \\> 40 kg\u002Fm2\n* Persons who cannot legally give consent\n* Pregnancy or lactation\n* History of severe mental or somatic disorders including neurological diseases (incl. epileptic seizures)\n* Taking psychotropic drugs\n* Chronic diseases or medication that influence glucose metabolism\n* Regular use of analgesic drugs\n* Previous bariatric surgery\n* Known allergy against one or more of the used agents\n* Acute infection and\u002For antibiotic treatment within the last 4 weeks\n* Hemoglobin values less than 10.5 g\u002Fdl for women, less than 11.5 g\u002Fdl for men\n* Other diseases that in the opinion of the investigator may jeopardize the success of the study or indicate a risk to the volunteer\n* Participation in a lifestyle intervention study or a pharmaceutical study within the last 30 days\n* Metal implants which cannot be removed as pacemakers, artificial heart valve, electrical devices as insulin pumps, large tattoos, retainer over more than 4 teeth, contraceptive coil, implanted magnetic metal parts as screws or plates after a surgery\n* Persons with claustrophobia\n* Persons with tinnitus\n* Weight loss or gain of \\>5% in the last 3 months\n* Pancreatic diseases\n* History or family history of multiple endocrine neoplasia (MEN2) or medullary thyroid cancer\n* History of malignant thyroid disease\n* History of malignant disease in the past 5 years\n* Surgery in the last three months\n* Chronic tobacco use of more than 10 cigarettes\u002Fday\n* Women who do not consent to refrain from breastfeeding until 2 months after the end of the study\n* Women of childbearing age who do not consent to use safe method of contraception from 28 days before until 2 months after the end of the study or refrain from heterosexual intercourse during this time\n* Women of childbearing age who do not consent to take a pregnancy test",true,"ALL","18 Years","70 Years",{"count":70,"type":71},60,"ESTIMATED","INTERVENTIONAL",[74],"NA","The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design. To this end, investigators will compare the effect of the administration of semaglutide versus placebo, followed by an fMRI with administration of intranasal insulin or placebo.",[77,78,79,80],"Normal Weight","Overweight and Obesity","Insulin Sensitivity","Insulin Resistance",[9,82,83,84],"Brain","functional magnetic resonance imaging","Semaglutide","2025-03-25",{"date":87,"type":88},"2025-03-30","ACTUAL",{"date":90,"type":88},"2024-07-01",{"date":92,"type":71},"2027-12-31",{"name":5,"class":6},1]